AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.98|
|52 Week High||US$5.44|
|52 Week Low||US$20.07|
|1 Month Change||0%|
|3 Month Change||-39.54%|
|1 Year Change||-56.00%|
|3 Year Change||-88.47%|
|5 Year Change||n/a|
|Change since IPO||-80.83%|
Recent News & Updates
We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
AVROBIO: Fabrazyme's Full Approval Changes Things
Photo by designer491/iStock via Getty Images AVROBIO (AVRO) has been having a bad spate lately due to no fault of its own. I covered it in December, and by January, the stock was up 30%; but then, in February, bluebird bio's (BLUE) trial was halted, and AVRO went down 30%
|AVRO||US Biotechs||US Market|
Return vs Industry: AVRO underperformed the US Biotechs industry which returned 26.1% over the past year.
Return vs Market: AVRO underperformed the US Market which returned 35.3% over the past year.
Stable Share Price: AVRO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: AVRO's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company’s lead product candidate is AVR-RD-01, a gene therapy which is in ongoing company-sponsored Phase 2 clinical trial and investigator-sponsored Phase 1 clinical trial for the treatment of Fabry disease.
AVROBIO Fundamentals Summary
|AVRO fundamental statistics|
Is AVRO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AVRO income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.82|
|Net Profit Margin||0.00%|
How did AVRO perform over the long term?See historical performance and comparison
Is AVROBIO undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AVRO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AVRO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AVRO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: AVRO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AVRO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AVRO is good value based on its PB Ratio (1.2x) compared to the US Biotechs industry average (3.3x).
How is AVROBIO forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVRO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AVRO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AVRO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AVRO is forecast to have no revenue next year.
High Growth Revenue: AVRO is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AVRO is forecast to be unprofitable in 3 years.
How has AVROBIO performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AVRO is currently unprofitable.
Growing Profit Margin: AVRO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AVRO is unprofitable, and losses have increased over the past 5 years at a rate of 43.6% per year.
Accelerating Growth: Unable to compare AVRO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVRO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: AVRO has a negative Return on Equity (-55.75%), as it is currently unprofitable.
How is AVROBIO's financial position?
Financial Position Analysis
Short Term Liabilities: AVRO's short term assets ($233.5M) exceed its short term liabilities ($17.0M).
Long Term Liabilities: AVRO's short term assets ($233.5M) exceed its long term liabilities ($150.0K).
Debt to Equity History and Analysis
Debt Level: AVRO is debt free.
Reducing Debt: AVRO has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AVRO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AVRO has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 42.8% each year.
What is AVROBIO current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AVRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AVRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVRO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVRO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AVRO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Geoff MacKay (55 yo)
Mr. Geoff MacKay, BSc, serves as Chief Executive Officer and President of AVROBIO Inc. He served as Director at RepliCel Life Sciences Inc. since December 2020 until 2021. Mr. MacKay serves as Chairman of...
CEO Compensation Analysis
Compensation vs Market: Geoff's total compensation ($USD4.90M) is above average for companies of similar size in the US market ($USD1.08M).
Compensation vs Earnings: Geoff's compensation has increased whilst the company is unprofitable.
Experienced Management: AVRO's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: AVRO's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AVRO insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.7%.
AVROBIO, Inc.'s employee growth, exchange listings and data sources
- Name: AVROBIO, Inc.
- Ticker: AVRO
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$260.866m
- Shares outstanding: 43.62m
- Website: https://www.avrobio.com
Number of Employees
- AVROBIO, Inc.
- Building 300
- Suite 201
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/25 22:03|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.